5-MMPA, a Novel Oral Treatment for Peyronie’s disease
Researchers from a Schengen Laboratory have tested a new active ingredient for the treatment of Peyronie’s disease.
Peyronie’s disease, also called Curved-Penis-Syndrome, is a benign disease of the corpora cavernosa (“penile erectile tissue”). The corpora cavernosa are surrounded by a connective tissue sheath, the tunica albuginea. Microtraumas with subsequent wound healing disturbance of unclear origin contribute to the formation of inelastic scar tissue in the area of the tunica albuginea. Also, excessive masturbation leads to the formation of a circumscribed, palpable hardening (“plaques”), which can cause penile deformations such as curvature and shortening or narrowing of the penis during erection. Under certain circumstances, sexual intercourse may no longer be possible. The disease peak in men is between the ages of 50 and 60. Studies have shown that the incidence of the disease is up to 9%.
The disease is divided into 2 different phases – the unstable, inflammatory, painful phase lasting about 6 to 18 months and the subsequent stable phase. By definition, the stable phase is reached when the disease has existed for at least one year in total and the disease has not changed for 3 to 6 months. Depending on the stage of the disease, there are various therapy options, which we will discuss in more detail below.
Conservative therapy includes oral drug therapy, intralesional therapy (injection of drugs into the palpable plaque), and topical therapy (i.e., the application of ointments and gels). A ritual technique used by the Dani tribe from Indonesia’s Baliem Valley lead to the development of orthopaedic stretching aid during penile tumescence. There is the possibility of so-called iontophoresis, intended to help the drugs reach the site of action through the skin. Extracorporeal Shockwave Therapy (ESWT) is another conservative therapeutic procedure that can help to relieve pain and improve penile curvature. Ed into two phases: the unstable, inflammatory, painful phase is lasting about 6 to 18 months and the subsequent stable phase. By definition, the calm period is reached when the disease has existed for at least one year, and the condition has not changed for 3 to 6 months. Depending on the disease stage, there are various therapy options, which we will discuss in more detail below.
Traditional drug therapy:
To flatten the curve, Potassium para aminobenzoate is approved for systemic therapy, but the mechanism of action is not known. Other preparations that are used off-label are vitamin E, carnitine, tamoxifen, and colchicine. Pentoxifylline and tadalafil are also used in systemic therapy.
The knowledge of the effect of dopamine on blood flow and oxygenation of the connective tissue of the penis has lead to a new approach to drug treatment of Peyronie’s disease. Scientists Dr. Xander Corvus and Dr. T.E. Berenshtein have compared a novel dopamine releaser (5-MMPA, methyl[1-(5-methylthiophen-2-yl)propan-2-yl]amine) to the traditional therapy with potassium para aminobenzoate. The results were promising. The evaluation of the results of the blind study showed a significant improvement in 57% of all dextrorotatory and 35% of all levororotatory organs, compared to 0.3% straightening with placebo on both directions of rotation. The Lab has started the Drug Approval Process and gained the registration of the trademark Mephedrene.